Clinical characteristics and prognostic factors of primary gastric lymphoma A retrospective study with 165 cases

被引:58
|
作者
Wang, Yi-Gao [1 ,2 ]
Zhao, Lin-Yong [1 ,2 ]
Liu, Chuan-Qi [3 ]
Pan, Si-Cheng [3 ]
Chen, Xiao-Long [1 ,2 ]
Liu, Kai [1 ,2 ]
Zhang, Wei-Han [1 ,2 ]
Yang, Kun [1 ,2 ]
Chen, Xin-Zu [1 ,2 ]
Zhang, Bo [1 ]
Chen, Zhi-Xin [1 ]
Chen, Jia-Ping [1 ]
Zhou, Zong-Guang [1 ,4 ]
Hu, Jian-Kun [1 ,2 ]
机构
[1] Sichuan Univ, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Lab Gastr Canc, 37 Guo Xue Xiang St, Chengdu 610041, Peoples R China
[3] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China
[4] Sichuan Univ, State Key Lab Biotherapy, Lab Digest Surg, West China Hosp, Chengdu, Peoples R China
基金
中国国家自然科学基金;
关键词
conservative treatment; primary gastric lymphomas; prognosis; surgical treatment; NON-HODGKINS-LYMPHOMA; PRIMARY GASTROINTESTINAL LYMPHOMA; B-CELL LYMPHOMA; GERMAN MULTICENTER; CLINICOPATHOLOGICAL CHARACTERISTICS; CONSERVATIVE MANAGEMENT; CHEMOTHERAPY; SURGERY;
D O I
10.1097/MD.0000000000004250
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma. This retrospective study aimed to analyze the clinical characteristics, prognostic factors, and roles of different treatment modalities in patients with PGL. From January 2003 to November 2014, 165 patients who were diagnosed with PGL at West China Hospital were enrolled in this study. The clinical features, treatment, and follow-up information were analyzed. In this study, diffuse large B-cell lymphoma (DLBCL) (108, 65.5%) and mucosa-associated lymphoid tissue (MALT) lymphoma (52, 31.5%) were two predominant histological subtypes. One-year and 5-year overall survival (OS) rates of all patients were 95.2% and 79.5%, respectively; in whom 110 (66.7%) underwent surgery, 110 (66.7%) received chemotherapy, 12 (7.3%) received radiotherapy, and 10 (6.1%) received Helicobacter pylori eradication. And 75 patients (45.5%) were treated with at least 2 different types of therapies. Elevated lactic dehydrogenase (LDH) levels, poor performance status (PS), advanced stage, International Prognostic Index (IPI) score >= 3, conservative treatment, and high-grade histological subtype were associated with worse prognosis in univariate analysis. Cox regression analysis showed that LDH levels, PS. staging, and histological subtype were independent predictors of survival outcomes. In the DLBCL type, 5-year OS was significantly better in the surgically treated group (80.1%) than that of patients conservatively treated (49.8%) (P=0.001). Surgical treatment had almost no impact on OS in the MALT type than conservative treatment (P=0.597). The proportion of patients received conservative treatment increased from 4.5% in period 1 to 51.7% in period 4. High LDH levels, poor PS, advanced staging, and malignant pathological type at diagnosis are significantly associated with poor OS. Our data suggest that surgery is superior in prognosis over conservative treatment in the DLBCL type, but not in the MALT type. Recently, conservative treatment is becoming more preferred approach in patients with PGL.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Clinicopathological characteristics, local treatment, and prognostic factors in IE/IIE primary breast lymphoma: a retrospective study of 67 patients
    Ruigang Feng
    Wenwen Huang
    Lixuan Chen
    Jie Min
    Wenjun Shu
    Yue Yu
    Xin Wang
    Xuchen Cao
    Bowen Liu
    World Journal of Surgical Oncology, 21
  • [32] Clinicopathological characteristics, local treatment, and prognostic factors in IE/IIE primary breast lymphoma: a retrospective study of 67 patients
    Feng, Ruigang
    Huang, Wenwen
    Chen, Lixuan
    Min, Jie
    Shu, Wenjun
    Yu, Yue
    Wang, Xin
    Cao, Xuchen
    Liu, Bowen
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [33] Prognostic Factors in Primary Gastric non-Hodgkin's Lymphoma - a Single-Center Retrospective Analysis of 103 Cases from China
    Zhang, Jian
    Hu, Xichun
    Liu, Xiaojian
    Wu, Xianghua
    Sun, Si
    Zhang, Qunling
    Zhao, Xinmin
    Ren, Hongzheng
    Hong, Xiaonan
    HEPATO-GASTROENTEROLOGY, 2010, 57 (101) : 989 - 996
  • [34] Clinical characteristics, prognostic factors, and histone deacetylase 6 expression in primary gastric diffuse large B-cell lymphoma
    Jin, Shenhe
    Liu, Hui
    Yang, Chunmei
    You, Liangshun
    Ding, Wei
    Qian, Wenbin
    Wei, Juying
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11280 - 11292
  • [35] Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases
    Qian, Jiejing
    Jin, Jie
    Luo, Hong
    Jin, Chunji
    Wang, Lei
    Qian, Wenbin
    Meng, Haitao
    HEMATOLOGY, 2017, 22 (08) : 472 - 476
  • [36] Clinical features and prognostic factors of primary gastrointestinal lymphoma
    Wang, Lingli
    Gao, Jinjie
    Chu, Hongling
    Jing, Hongmei
    ASIAN JOURNAL OF SURGERY, 2024, 47 (05) : 2255 - 2256
  • [37] Prognostic factors for severe acute respiratory syndrome: A clinical analysis of 165 cases
    Zou, ZS
    Yang, YP
    Chen, JM
    Xin, SJ
    Zhang, W
    Zhou, XZ
    Mao, YL
    Hu, LP
    Liu, DJ
    Chang, BX
    Chang, WH
    Liu, YP
    Ma, XM
    Wang, YD
    Liu, XQ
    CLINICAL INFECTIOUS DISEASES, 2004, 38 (04) : 483 - 489
  • [38] Clinical characteristics and prognostic nomogram analysis of patients with dual primary cancers with first gastric cancer: a retrospective study in China
    Wang, Bing
    Liu, Lu
    PEERJ, 2023, 11
  • [39] STUDY ON 34 CASES WITH PRIMARY MALIGNANT GASTRIC LYMPHOMA
    Natori, Kazuhiko
    Ishihara, Susumu
    Nagase, Daisuke
    Shibuya, Akiko
    Toyoda, Yukitoshi
    Fujimoto, Yoshinori
    Kuraishi, Yasunobu
    Shibuya, Kazutoshi
    Izumi, Haruka
    ANNALS OF ONCOLOGY, 2012, 23 : 68 - 68
  • [40] Clinical Characteristics and Prognostic Factors for Adult HIV-Negative Burkitt Lymphoma: a Single-Center Retrospective Study
    Lai, Guanzhen
    Zhang, Rongshan
    CLINICAL LABORATORY, 2024, 70 (11) : 2055 - 2062